Canadian Diabetes & Endocrinology Today, Год журнала: 2025, Номер unknown
Опубликована: Май 8, 2025
As of 2018 data, 30–60% reproductive‑aged women in Canada were affected by overweight (body mass index [BMI] 25.9–29.9) and obesity (BMI >30.0), these rates are increasing. Obesity during pregnancy is associated with higher preeclampsia, gestational diabetes, macrosomia, stillbirth, post‑term pregnancy, increased caesarean delivery rates. also which has well‑known consequences for ovulatory dysfunction, impacts fertility, such as polycystic ovarian syndrome (PCOS). Addressing its metabolic could have a profound effect on reproductive fetal health. Since the 2000s, incretin-based therapies diabetes become focus research clinical practice. Glucagon‑like‑peptide 1 (GLP-1), an endogenous incretin hormone secreted intestinal L-cells response to food intake, agonists, been available use since introduction liraglutide 2011. Recently, pharmacologic agonists glucose-dependent insulinotropic polypeptide (GIP), synthesized K-cells duodenum jejunum, available. Dual agonism hormones more significant reductions blood glucose weight. The currently listed Table 1, their physiologic effects summarized Figure 1. Active underway new molecules, example amylin glucagon, various combinations GLP‑1 GIP, maximize benefits. These shown weight loss rivalling those surgery. Considering potential, this medication class taken world storm. Canada's Drug Agency (CDA) found that expenditure injectable semaglutide, under brand-name Ozempic™, from $13.5 million 2019 $227 2021, 20% claims being non-type 2 use. improvements achieved improved fertility. While product monographs warn against lactation, conception while treatments becoming common. increasing reality, review aims summarize what known about GLP-1 GIP pregnancy.
Язык: Английский